Pieris Pharmaceuticals, Inc. is a biopharmaceutical firm in the clinical development stage, dedicated to discovering and advancing drugs based on its proprietary Anticalin technology. These Anticalin proteins are therapeutic, low-molecular-weight molecules derived from naturally occurring human lipocalins, which are found in blood plasma and other bodily fluids. The company's pipeline includes several key drug candidates: Respiratory: PRS-060/AZD1402: A lead Anticalin candidate currently in Phase II clinical trials, targeting IL-4Ra for the treatment of asthma and various inflammatory diseases. PRS-220: An orally inhaled Anticalin protein designed to target connective tissue growth factor, intended for the treatment of idiopathic pulmonary fibrosis (IPF). Immuno-Oncology: Cinrebafusp alfa: A bispecific drug targeting both 4-1BB and HER2, developed for gastric cancers that express high or low levels of HER2. PRS-344/S095012: A bispecific Anticalin-antibody fusion protein in Phase I clinical trials, targeting 4-1BB and PD-L1 for various immuno-oncology indications. PRS-352: A preclinical-stage program focusing on undisclosed targets within immuno-oncology. Pieris has established several strategic partnerships, including collaboration and licensing agreements with Les Laboratoires Servier (and Institut de Recherches Internationales Servier), AstraZeneca AB, and Seagen Inc. Further licensing agreements are in place with the Technical University of Munich, Enumeral Biomedical Holdings, Inc., and Sichuan Kelun-Biotech Biopharmaceutical Co. Ltd. Additionally, the company has a clinical trial collaboration and supply agreement with Eli Lilly and Company. Established in 2000, Pieris Pharmaceuticals, Inc. maintains its headquarters in Boston, Massachusetts.